The Alzheimer’s Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Alzheimer’s Disease Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alzheimer’s Disease Market.

Some of the key takeaways from the Alzheimer’s Disease Pipeline Report: 

• Companies across the globe are diligently working toward developing novel Alzheimer’s Disease treatment therapies with a considerable amount of success over the years. 

• Alzheimer’s Disease companies working in the treatment market are Neurodon, Sangamo Therapeutics, NKGen Biotech, Asceneuron, TrueBinding, Alector, Cognition Therapeutics, Anavex Life Sciences, Eisai Co Ltd, Cassava Sciences, Inc., Karuna Therapeutics, BioVie, and others, are developing therapies for the Alzheimer’s Disease treatment 

• Emerging Alzheimer’s Disease therapies in the different phases of clinical trials are- NRDN-201, ST-501, SNK 01, ASN51, TB 006, AL002, CT-1812, Blarcamesine, E 2814, Simufilam, KarXT, NE3107, and others are expected to have a significant impact on the Alzheimer’s Disease market in the coming years.   

• In March 2024, MapLight Therapeutics, a clinical-stage biopharmaceutical company focused on developing targeted novel treatments for debilitating CNS disorders, announced the start of a Phase 1 clinical trial for ML-007/PAC. This is an extended-release fixed-dose combination of the novel investigational muscarinic agonist ML-007 and a precision-matched peripherally active anticholinergic (PAC). The trial builds on findings from three previous Phase 1 trials that assessed the safety and tolerability of ML-007 with PAC. The data from this new trial will guide the dosing regimen for upcoming Phase 2 trials targeting schizophrenia and Alzheimer’s disease psychosis. The company plans to start its first Phase 2 trial of ML-007/PAC in schizophrenia later this year.

• In January 2024, AmyriAD Therapeutics plans to assess its leading Alzheimer’s disease small molecule candidate, AD-101, in three forthcoming Phase III studies.

• In July 2023, Following a conclusion that a confirmatory trial demonstrated clinical benefit, the U.S. Food and Drug Administration converted Leqembi (lecanemab-irmb), intended to treat adult patients with Alzheimer’s Disease, to conventional approval. Leqembi is the first amyloid beta-directed antibody for the treatment of Alzheimer’s disease to transition from an accelerated approval to a conventional approval.

Alzheimer’s Disease Overview

Alzheimer’s disease is a progressive neurodegenerative disorder that primarily affects older adults, leading to cognitive decline, memory loss, and changes in behavior and personality. It is the most common cause of dementia, accounting for 60-80% of dementia cases.

Get a Free Sample PDF Report to know more about Alzheimer’s Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/alzheimers-disease-ad-pipeline-insight

Emerging Alzheimer’s Disease Drugs Under Different Phases of Clinical Development Include:

• NRDN-201: Neurodon

• ST-501: Sangamo Therapeutics

• SNK 01: NKGen Biotech

• ASN51: Asceneuron

• TB 006: TrueBinding

• AL002: Alector

• CT-1812: Cognition Therapeutics

• Blarcamesine: Anavex Life Sciences

• E 2814: Eisai Co Ltd

• Simufilam: Cassava Sciences, Inc.

• KarXT: Karuna Therapeutics

• NE3107: BioVie

Alzheimer’s Disease Route of Administration

Alzheimer’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Alzheimer’s Disease Molecule Type

Alzheimer’s Disease Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy 

Alzheimer’s Disease Pipeline Therapeutics Assessment

• Alzheimer’s Disease Assessment by Product Type

• Alzheimer’s Disease By Stage and Product Type

• Alzheimer’s Disease Assessment by Route of Administration

• Alzheimer’s Disease By Stage and Route of Administration

• Alzheimer’s Disease Assessment by Molecule Type

• Alzheimer’s Disease by Stage and Molecule Type

DelveInsight’s Alzheimer’s Disease Report covers around 120+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Alzheimer’s Disease product details are provided in the report. Download the Alzheimer’s Disease pipeline report to learn more about the emerging Alzheimer’s Disease therapies

Some of the key companies in the Alzheimer’s Disease Therapeutics Market include:

Key companies developing therapies for Alzheimer’s Disease are – AbbVie, Inc., Teva Pharmaceuticals Ltd., Eisai Co., Ltd., Janssen Pharmaceuticals, Inc., Johnson & Johnson, Novartis AG, Zydus Lifesciences Ltd (CADILA), Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd, Aurobindo Pharma Ltd, Amneal Pharmaceuticals Inc., Macleods Pharmaceuticals Ltd., Viatris Inc., Lupin Ltd, Cipla Ltd., Torrent Pharmaceuticals Ltd., Unichem laboratories ltd, Lannett Inc., and others.

Alzheimer’s Disease Pipeline Analysis:

The Alzheimer’s Disease pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Alzheimer’s Disease with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alzheimer’s Disease Treatment.

• Alzheimer’s Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Alzheimer’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alzheimer’s Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Alzheimer’s Disease drugs and therapies

Alzheimer’s Disease Pipeline Market Drivers

• Increase in prevalence of Alzheimer’s Disease (AD), rising geriatric population are some of the important factors that are fueling the Alzheimer’s Disease Market.

Alzheimer’s Disease Pipeline Market Barriers

• However, clinical trials are more complicated, costly, and slower than trials for other diseases., lack of clear diagnosis and other factors are creating obstacles in the Alzheimer’s Disease Market growth.

Scope of Alzheimer’s Disease Pipeline Drug Insight    

• Coverage: Global

• Key Alzheimer’s Disease Companies: Neurodon, Sangamo Therapeutics, NKGen Biotech, Asceneuron, TrueBinding, Alector, Cognition Therapeutics, Anavex Life Sciences, Eisai Co Ltd, Cassava Sciences, Inc., Karuna Therapeutics, BioVie, and others

• Key Alzheimer’s Disease Therapies: NRDN-201, ST-501, SNK 01, ASN51, TB 006, AL002, CT-1812, Blarcamesine, E 2814, Simufilam, KarXT, NE3107, and others

• Alzheimer’s Disease Therapeutic Assessment: Alzheimer’s Disease current marketed and Alzheimer’s Disease emerging therapies

• Alzheimer’s Disease Market Dynamics: Alzheimer’s Disease market drivers and Alzheimer’s Disease market barriers 

Request for Sample PDF Report for Alzheimer’s Disease Pipeline Assessment and clinical trials

Table of Contents 

1. Alzheimer’s Disease Report Introduction

2. Alzheimer’s Disease Executive Summary

3. Alzheimer’s Disease Overview

4. Alzheimer’s Disease- Analytical Perspective In-depth Commercial Assessment

5. Alzheimer’s Disease Pipeline Therapeutics

6. Alzheimer’s Disease Late Stage Products (Phase II/III)

7. Alzheimer’s Disease Mid Stage Products (Phase II)

8. Alzheimer’s Disease Early Stage Products (Phase I)

9. Alzheimer’s Disease Preclinical Stage Products

10. Alzheimer’s Disease Therapeutics Assessment

11. Alzheimer’s Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Alzheimer’s Disease Key Companies

14. Alzheimer’s Disease Key Products

15. Alzheimer’s Disease Unmet Needs

16 . Alzheimer’s Disease Market Drivers and Barriers

17. Alzheimer’s Disease Future Perspectives and Conclusion

18. Alzheimer’s Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/